MDXG Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
MDXG is not a good buy right now for a Beginner investor focused on the long term with $50,000-$100,000 to deploy. The stock has already been hit by a major earnings miss and guidance reset, and while analysts still lean positive overall, the near-term fundamentals and trend are still too unstable for a clear buy. I would not buy it today; hold off until the business shows clearer revenue stabilization.
Pre-market price is 3.55, sitting just above pivot resistance/support clustering around 3.573. RSI_6 at 49.811 is neutral, MACD histogram is slightly positive but contracting, and moving averages are converging. That combination points to a range-bound, indecisive setup rather than a strong uptrend. Key levels: resistance at 3.705 and 3.787, support at 3.442 and 3.36. The short-term trend model is only modestly constructive, with projected upside of 1.75% next week and 2.22% next month, which is not enough to justify an immediate long-term buy after a major downside shock.
["Several analysts still keep Buy/Outperform/Overweight ratings despite lowering price targets.", "Lake Street believes the worst may already be priced in and sees Surgical value exceeding current market cap.", "Citizens and Craig-Hallum view reimbursement disruptions as temporary and expect eventual recovery.", "The company announced about $40M in annualized opex reductions, which may support margins over time.", "Short-term technicals are not bearish enough to rule out a rebound, with MACD still slightly positive."]
["Q1 2026 EPS of -0.05 and revenue of $59M missed estimates.", "Revenue fell 33.1% year over year, showing a sharp deterioration in growth.", "Full-year 2026 sales guidance was cut to $260M-$290M due to market disruptions.", "Medicare reimbursement changes are disrupting demand and ordering patterns in wound care.", "The stock dropped 9.26% after earnings, confirming negative market reaction.", "Hedge funds and insiders are both neutral, showing no supportive trading trend."]
Latest quarter: Q1 2026. Financials were weak, with non-GAAP EPS of -0.05 and revenue of $59 million, down 33.1% year over year and below expectations. Management also cut full-year 2026 net sales guidance to $260 million-$290 million, which implies ongoing top-line pressure rather than a recovery already in place. The company is taking cost cuts, but the latest quarter shows contraction, not growth.
Recent analyst trend is still constructive on rating but clearly negative on price targets. Craig-Hallum, Lake Street, Citizens, Northland, and Cantor all reduced targets, mostly into the $5-$7 range, while maintaining Buy/Outperform/Overweight-type ratings. Wall Street's pro view is that the reimbursement shock is temporary, the worst may be priced in, and Surgical has long-term value. The con view is that Wound Care remains under pressure, guidance was cut, and estimate revisions show the recovery is taking longer than hoped. Overall, pros remain optimistic on long-term recovery, but the target cuts show fading near-term confidence.
